Gerhard Arold

591 total citations
18 papers, 458 citations indexed

About

Gerhard Arold is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Gerhard Arold has authored 18 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Surgery. Recurrent topics in Gerhard Arold's work include Diabetes Management and Research (4 papers), Diabetes Treatment and Management (4 papers) and Pancreatic function and diabetes (4 papers). Gerhard Arold is often cited by papers focused on Diabetes Management and Research (4 papers), Diabetes Treatment and Management (4 papers) and Pancreatic function and diabetes (4 papers). Gerhard Arold collaborates with scholars based in Germany, Denmark and Hungary. Gerhard Arold's co-authors include Ivar Roots, Steffen Bauer, Konstanze Diefenbach, Carsten Roepstorff, Hanne Haahr, Viera Kupčová, Jürgen Schmider, Jürgen Brockmöller, Susanne Gammelgaard Bøttcher and Julie Hjerpsted and has published in prestigious journals such as Journal of Hepatology, Annals of the Rheumatic Diseases and Clinical Pharmacokinetics.

In The Last Decade

Gerhard Arold

18 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gerhard Arold Germany	11	145	122	94	92	85	18	458
J. Harris United States	8	55 0.4×	114 0.9×	98 1.0×	66 0.7×	38 0.4×	10	355
Ramakrishnan Veerabathiran India	10	42 0.3×	126 1.0×	37 0.4×	48 0.5×	43 0.5×	82	436
Zhengbo Duanmu United States	12	90 0.6×	132 1.1×	162 1.7×	88 1.0×	56 0.7×	18	423
J Gosset United States	12	13 0.1×	72 0.6×	150 1.6×	130 1.4×	83 1.0×	40	489
Ingrid Påhlman Sweden	11	12 0.1×	123 1.0×	73 0.8×	152 1.7×	102 1.2×	19	457
Michiyasu Ishizawa Japan	12	49 0.3×	159 1.3×	22 0.2×	110 1.2×	89 1.0×	25	468
Yibo Wen China	10	29 0.2×	116 1.0×	12 0.1×	15 0.2×	36 0.4×	33	423
Antonio Maria Borzì Italy	12	66 0.5×	119 1.0×	10 0.1×	102 1.1×	53 0.6×	24	475
Katarina Tomović Serbia	10	107 0.7×	139 1.1×	41 0.4×	81 0.9×	52 0.6×	18	360
Yusuf Ziya İğci Türkiye	14	29 0.2×	210 1.7×	52 0.6×	28 0.3×	56 0.7×	35	488

Countries citing papers authored by Gerhard Arold

Since Specialization

Citations

This map shows the geographic impact of Gerhard Arold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerhard Arold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerhard Arold more than expected).

Fields of papers citing papers by Gerhard Arold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerhard Arold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerhard Arold. The network helps show where Gerhard Arold may publish in the future.

Co-authorship network of co-authors of Gerhard Arold

This figure shows the co-authorship network connecting the top 25 collaborators of Gerhard Arold. A scholar is included among the top collaborators of Gerhard Arold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerhard Arold. Gerhard Arold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Roupe, Kathryn, et al.. (2024). Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions. Clinical and Translational Science. 17(5). e13810–e13810. 3 indexed citations

Chen, Hubert, et al.. (2019). SAT-341-MET409, an optimized sustained FXR agonist, was safe and well-tolerated in a 14-day phase 1 study in healthy subjects. Journal of Hepatology. 70(1). e789–e789. 6 indexed citations

Seitz, Lisa, Lixia Jin, Manmohan R. Leleti, et al.. (2018). Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Investigational New Drugs. 37(4). 711–721. 48 indexed citations

Xiao, Jim, Dorota Nowak, Rodryg Ramlau, et al.. (2018). Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor. Clinical and Translational Science. 12(1). 58–65. 19 indexed citations

Jensen, Lene, Viera Kupčová, Gerhard Arold, Jonas Pettersson, & Julie Hjerpsted. (2017). Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes Obesity and Metabolism. 20(4). 998–1005. 48 indexed citations

Joly, Sandrine, Jacky Vonderscher, Patrice André, et al.. (2017). The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. Journal of Hepatology. 66(1). S690–S690. 11 indexed citations

Beneden, Katrien Van, et al.. (2014). FRI0329 Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with Alx-0061: Post-Hoc Analysis of Phase I/Ii Data. Annals of the Rheumatic Diseases. 73. 506–506. 1 indexed citations

Phelan, Mary C., Judith Anzures‐Cabrera, David Carlile, et al.. (2013). Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dalcetrapib. Clinical Pharmacokinetics. 52(4). 255–265. 10 indexed citations

Kiss, István, et al.. (2013). Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment. Clinical Pharmacokinetics. 53(2). 175–183. 53 indexed citations

10.

Kupčová, Viera, et al.. (2013). Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment. Clinical Drug Investigation. 34(2). 127–133. 32 indexed citations

11.

Holz, Josefin-Beate, Bernadette Rojkovich, Mariusz Korkosz, et al.. (2013). OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA. Annals of the Rheumatic Diseases. 72. A64–A64. 18 indexed citations

12.

Kiss, István, et al.. (2012). Insulin Degludec has Similar Pharmacokinetic Properties in Subjects with Renal Impairment and Subjects with Normal Renal Function. Canadian Journal of Diabetes. 36(5). S36–S36. 9 indexed citations

13.

Arold, Gerhard, et al.. (2012). Insulin Degludec has Similar Pharmacokinetic Properties in Subjects with Hepatic Impairment when Compared to Subjects with Normal Hepatic Function. Canadian Journal of Diabetes. 36(5). S36–S36. 7 indexed citations

14.

Arold, Gerhard, Frank Donath, Konstanze Diefenbach, et al.. (2005). No Relevant Interaction with Alprazolam, Caffeine, Tolbutamide, and Digoxin by Treatment with a Low-Hyperforin St John’s Wort Extract. Planta Medica. 71(4). 331–337. 70 indexed citations

15.

Diefenbach, Konstanze, et al.. (2005). Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥ 50 years. British Journal of Urology. 95(3). 346–349. 54 indexed citations

16.

Johne, Andreas, Gerhard Arold, Sebastian Bauer, et al.. (2003). Interaktionen zwischen Phytopharmaka und anderen Arzneimitteln. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 46(12). 1061–1067. 1 indexed citations

17.

Schmider, Jürgen, Jürgen Brockmöller, Gerhard Arold, Steffen Bauer, & Ivar Roots. (1999). Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics and Genomics. 9(6). 725–734. 63 indexed citations

18.

ller, J rgen Brockm, et al.. (1999). Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics. 9(6). 725???734–725???734. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact